NasdaqGS:TARSPharmaceuticals
Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus
In early August 2026, Tarsus Pharmaceuticals reported second-quarter revenue of US$173.91 million and a net loss of US$18.55 million, while also raising full-year 2026 XDEMVY net product sales guidance to US$685 million–US$705 million.
The earnings update highlighted strong XDEMVY uptake, with more than 700,000 patients treated since launch and an acquisition of Alkeus Pharmaceuticals to broaden Tarsus’ ophthalmology pipeline.
We’ll now examine how this stronger XDEMVY sales outlook and...